GRITSTONE BIO, INC.

(GRTS)
  Report
Delayed Nasdaq  -  04:00 2022-08-18 pm EDT
4.490 USD   +2.51%
08/17Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
08/15Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors
AQ
08/15Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2000 Value Index

06/24/2022 | 12:00am EDT

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2000 Value Index


© S&P Capital IQ 2022
All news about GRITSTONE BIO, INC.
08/17Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
08/15Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of GRANI..
AQ
08/15Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study..
CI
08/10GRITSTONE BIO : Appoints Dr. Lawrence “Larry” Corey to its Board of Directors ..
PU
08/10GRITSTONE BIO, INC. : Change in Directors or Principal Officers, Financial Statements and ..
AQ
08/10Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors
AQ
08/10Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effe..
CI
08/04GRITSTONE BIO : Reports Second Quarter 2022 Financial Results and Provides Business Update..
PU
08/04GRITSTONE BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
08/04Earnings Flash (GRTS) GRITSTONE BIO Reports Q2 Revenue $5.5M
MT
More news
Analyst Recommendations on GRITSTONE BIO, INC.
More recommendations
Financials (USD)
Sales 2022 19,2 M - -
Net income 2022 -123 M - -
Net cash 2022 23,0 M - -
P/E ratio 2022 -2,90x
Yield 2022 -
Capitalization 328 M 328 M -
EV / Sales 2022 15,9x
EV / Sales 2023 23,6x
Nbr of Employees 193
Free-Float 97,0%
Chart GRITSTONE BIO, INC.
Duration : Period :
Gritstone bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GRITSTONE BIO, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 4,49 $
Average target price 11,33 $
Spread / Average Target 152%
EPS Revisions
Managers and Directors
Andrew R. Allen President, Chief Executive Officer & Director
Vassiliki Celia Economides Chief Financial Officer & Executive Vice President
Elaine V. Jones Chairman
Karin Jooss Head-Research & Development
Erin E. Jones Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
GRITSTONE BIO, INC.-65.94%320
CSL LIMITED0.61%97 468
SAMSUNG BIOLOGICS CO.,LTD.-3.10%47 101
WUXI BIOLOGICS (CAYMAN) INC.-24.64%37 923
BIOGEN INC.-9.31%31 574
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-25.52%22 656